ArticleScientific reports2025
Molecules interacting with CasL-Like 2 enhances tumor angiogenesis and progression by activating mTOR/HIF1α/VEGF pathway in kidney renal clear cell carcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Kidney renal clear cell carcinoma (KIRC), as one of the most angiogenically active urological tumors, has not yet been fully elucidated its molecular mechanisms. Molecules interacting with CasL-Like 2 (MICAL-L2), a unique oxidoreductase, is known to be involved in cytoskeletal regulation. However, its role and mechanism in tumor angiogenesis remain unclear. This study aims to reveal the specific mechanism by which MICAL-L2 regulates KIRC angiogenesis through cytoskeletal dynamics and to explore its clinical translational value and significance. Bioinformatics database analysis showed that MICAL-L2 was significantly overexpressed in various solid tumors and was closely associated with shorter overall survival in KIRC patients. Gene set enrichment analysis demonstrated that MICAL-L2 expression was significantly correlated with members of the hypoxia-inducible factor (HIF) family and was closely related to angiogenesis pathways. Analysis of human KIRC cell lines revealed that the upregulation of MICAL-L2 stimulated the release of various pro-angiogenic cytokines, primarily through the activation of a novel mTOR/HIF1α/VEGF pathway, promoting tumor angiogenesis. Further studies using cultured KIRC cell lines unveiled that MICAL-L2 co-localized with F-actin in the cytoplasm and promoted tumor angiogenesis remodeling in vitro. Additionally, analysis of clinical datasets indicated that high expression of MICAL-L2 was associated with drug resistance to various anti-angiogenic agents and actin inhibitors in cancer. This study reveals a new mechanism in which MICAL-L2, under the tumor hypoxic environment, promotes KIRC angiogenesis and progression by activating the "cytoskeletal remodeling-mTOR/HIF1α/VEGF signaling pathway" using integrated analysis of clinical samples and cell models, providing new theoretical evidence and potential intervention targets for the development of combination therapies targeting the tumor microenvironment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.